Ribozyme Therapy: RNA Enzymes to the Rescue

Overview

Journal Yale J Biol Med

Specialty Biology

Date 2003 Jun 6

PMID 12784972

Authors

Antony M Jose

Affiliations

Soon will be listed here.

References

Usman N, Blatt L . Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J Clin Invest. 2000; 106(10):1197-202. PMC: 381444. DOI: 10.1172/JCI11631. View

Bauer G, Valdez P, Kearns K, Bahner I, Wen S, Zaia J . Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood. 1997; 89(7):2259-67. View

Winkler W, Nahvi A, Breaker R . Thiamine derivatives bind messenger RNAs directly to regulate bacterial gene expression. Nature. 2002; 419(6910):952-6. DOI: 10.1038/nature01145. View

Wong-Staal F, Poeschla E, Looney D . A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther. 1998; 9(16):2407-25. DOI: 10.1089/hum.1998.9.16-2407. View

Sullenger B, Gilboa E . Emerging clinical applications of RNA. Nature. 2002; 418(6894):252-8. DOI: 10.1038/418252a. View

Nissen P, Hansen J, Ban N, Moore P, Steitz T . The structural basis of ribosome activity in peptide bond synthesis. Science. 2000; 289(5481):920-30. DOI: 10.1126/science.289.5481.920. View

Pavco P, Bouhana K, Gallegos A, Agrawal A, Blanchard K, Grimm S . Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res. 2000; 6(5):2094-103. View

Forster A, Symons R . Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site. Cell. 1987; 50(1):9-16. DOI: 10.1016/0092-8674(87)90657-x. View

Zaug A, Been M, Cech T . The Tetrahymena ribozyme acts like an RNA restriction endonuclease. Nature. 1986; 324(6096):429-33. DOI: 10.1038/324429a0. View

10.

Fedor M, Uhlenbeck O . Substrate sequence effects on "hammerhead" RNA catalytic efficiency. Proc Natl Acad Sci U S A. 1990; 87(5):1668-72. PMC: 53543. DOI: 10.1073/pnas.87.5.1668. View

11.

Zuker M . Computer prediction of RNA structure. Methods Enzymol. 1989; 180:262-88. DOI: 10.1016/0076-6879(89)80106-5. View

12.

Cotten M, Birnstiel M . Ribozyme mediated destruction of RNA in vivo. EMBO J. 1989; 8(12):3861-6. PMC: 402074. DOI: 10.1002/j.1460-2075.1989.tb08564.x. View

13.

Hertel K, Herschlag D, Uhlenbeck O . A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry. 1994; 33(11):3374-85. DOI: 10.1021/bi00177a031. View

14.

Milligan J, Jones R, Froehler B, Matteucci M . Development of antisense therapeutics. Implications for cancer gene therapy. Ann N Y Acad Sci. 1994; 716:228-41. DOI: 10.1111/j.1749-6632.1994.tb21715.x. View

15.

Nahvi A, Sudarsan N, Ebert M, Zou X, Brown K, Breaker R . Genetic control by a metabolite binding mRNA. Chem Biol. 2002; 9(9):1043. DOI: 10.1016/s1074-5521(02)00224-7. View

16.

Kruger K, Grabowski P, Zaug A, Sands J, Gottschling D, Cech T . Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell. 1982; 31(1):147-57. DOI: 10.1016/0092-8674(82)90414-7. View

17.

Han J, Zhu Z, Hsu C, Finley W . Selection of antisense oligonucleotides on the basis of genomic frequency of the target sequence. Antisense Res Dev. 1994; 4(1):53-65. DOI: 10.1089/ard.1994.4.53. View

18.

Breaker R . In Vitro Selection of Catalytic Polynucleotides. Chem Rev. 1997; 97(2):371-390. DOI: 10.1021/cr960008k. View

19.

Beigelman L, McSwiggen J, Draper K, Gonzalez C, Jensen K, Karpeisky A . Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem. 1995; 270(43):25702-8. DOI: 10.1074/jbc.270.43.25702. View

20.

Jose A, Soukup G, Breaker R . Cooperative binding of effectors by an allosteric ribozyme. Nucleic Acids Res. 2001; 29(7):1631-7. PMC: 31269. DOI: 10.1093/nar/29.7.1631. View